perindopril erbumine  (MedChemExpress)

Journal: Scientific Reports

Article Title: Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy

doi: 10.1038/s41598-024-51572-z

Figure Lengend Snippet: Effects of daily treatment with representative ARB, ACEI and CaB on the development of DPN in leptin-deficient ob / ob mice. Tactile ( A and B ) and thermal ( C and D ) nociceptive sensitivities and blood glucose levels ( E ) were determined in ob / ob mice and the control age-matched lean mice between 5 and 12 weeks of age. Telmisartan at 5 mg/kg, perindopril at 2 mg/kg or amlodipine at 3 mg/kg was administered i.p. to ob / ob mice once daily for 6 weeks (i.e. until the age of 12 weeks), starting at the age of 6 weeks. AUC values between 9 and 12 weeks of age, ( B ) and ( D ), were calculated from the time-related changes in paw-withdrawal threshold ( A ) and paw-withdrawal latency ( C ). Values represent the means ± SEM for 8 mice per group.

Article Snippet: Three different antihypertensive agents, i.e. perindopril erbumine (Sigma-Aldrich, St. Louis, MO, USA), an ACEI, telmisartan (FUJIFILM Wako Pure Chemical, Osaka, Japan), an ARB, and amlodipine besylate (Tokyo Chemical Industry, Tokyo, Japan), an L-type calcium channel blocker (CaB), were used to test their effects on the development of DPN in the ob / ob mice.

Techniques: